Tag Archives: ZIOP

Top 10 Medical Stocks To Own For 2021

After attending its investor update, Raymond James analysts Savanthi Syth and Matt Roberts see a “pathway to substantial and sustainable shareholder value creation” at Delta Air Lines (DAL). They explain:

Bloomberg News

Delta held its fourth mid-year investor update primarily focused on providing updated capital deployment targets. The cash flow and capital deployment commentary in general was better than our, and we believe consensus, expectations and continues to position Delta with a lower-risk business model that should generate profitability and shareholder value through the business cycle…

Financial targets (largely in-line): We had anticipated Delta to raise its three-year margin/ROIC targets (and, in turn, operating cash flow) based on lower-for-longer fuel expectation. The targets were generally in-line with our 2016/17 forecasts. An exception was our lower 2017E operating cash flow, but this was due to a much higher cash tax rate assumption. In a positive surprise, Delta noted its cash tax rate is expected to be 20% compared to the book tax rate of 35%. While the financial forecasts were largely in-line with our expectations, they are likely to be met with skepticism by some investors due to concerns about the industrys ability to recover anticipated rising fuel prices or the potential for substantial weakening of demand from current levels (or both!)…

Top 10 Medical Stocks To Own For 2021: Tetra Technologies, Inc.(TTI)

The financial statements presented in this Annual Report are the consolidated financial statements of TETRA Technologies, Inc., a Delaware corporation and its subsidiaries. When the terms “TETRA,” “the Company,” “we,” “us,” or “our” are used in this document, those terms refer to TETRA Technologies, Inc. and its consolidated subsidiaries.
TETRA is a Delaware corporation, incorporated in 1981. Our corporate headquarters are located at 24955 Interstate 45 North in The Woodlands, Texas. Our phone number is 281-367-1983, and our website is accessed at www.tetratec.com. Our common stock is traded on the New York Stock Exchange under the symbol “TTI.   Advisors’ Opinion:

  • [By Max Byerly]

    TETRA Technologies, Inc. (NYSE:TTI) dropped 5.3% during trading on Wednesday . The company traded as low as $3.89 and last traded at $3.90. Approximately 647,036 shares were traded during trading, a decline of 14% from the average daily volume of 752,548 shares. The stock had previously closed at $4.12.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on TETRA Technologies (TTI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Medical Stocks To Own For 2021: Omega Healthcare Investors, Inc.(OHI)

Omega Healthcare Investors, Inc. (“Omega,” “we,” “our” or the “Company”) was incorporated in the State of Maryland on March 31, 1992. We are a self-administered real estate investment trust (“REIT”), investing in income producing healthcare facilities, principally long-term care facilities located in the United States and the United Kingdom. We provide lease or mortgage financing to qualified operators of skilled nursing facilities (“SNFs”) and, to a lesser extent, assisted living facilities (“ALFs”), independent living facilities and rehabilitation and acute care facilities. We have historically financed investments through borrowings under our revolving credit facilities, private placements or public offerings of our debt and equity securities, the assumption of secured indebtedness, retention of cash flow, or a combination of these methods.   Advisors’ Opinion:

  • [By Nicholas Rossolillo, Chuck Saletta, and Daniel Miller]

    That’s not always the case, though. An above-average yield can also be an indicator that all’s not right for a business. Carefully selecting which stocks make the cut as part of a high-yield portfolio is an important step. Three Foolish contributors are here to help. They think CenturyLink (NYSE:CTL), Omega Healthcare Investors(NYSE:OHI), andPublic Storage(NYSE:PSA) are worth considering.

  • [By Reuben Gregg Brewer]

    Shares of Omega Healthcare Investors, Inc. (NYSE:OHI) fell roughly 10% in February according to data provided by S&P Global Market Intelligence. Although many healthcarereal estate investment trusts, or REITs, had a rough month, nursing-home-focused Omega’s loss was particularly bad. Most of the drop occurred on the day the REIT announced earnings.

  • [By Motley Fool Transcribing]

    Omega Healthcare Investors (NYSE:OHI) Q4 2018 Earnings Conference CallFeb. 12, 2019 10:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Garrett Baldwin]

    To see why we believe some of the richest players in the world are preparing for a market collapse, click here.

    Stocks to Watch Today: AMZN, NFLX, AAPL
    Democrats have been enraged by the sweetheart deal given to Amazon.com Inc. (NASDAQ: AMZN) in New York City. Now, independents like former mayor Michael Bloomberg have criticized the billions in subsidies given to the e-commerce giant. Well, Amazon has responded. The company’s executive team is now reevaluating its planned campus in Long Island City, and it could leave the region under pressure. Last week, JPMorgan Chase & Co. (NYSE: JPM) released a report that recommended one of the deals of the decade. The bank has called for Apple Inc. (NASDAQ: AAPL) to buy streaming giant Netflix Inc. (NASDAQ: NFLX). This deal is a no-brainer in today’s market. We break down what a deal would look like, how it benefits both sides, and how it would be like rocket fuel for Apple stock. Here’s what you need to know. Look for earnings reports from Brighthouse Financial Inc. (NYSE: BHF), Everest Re Group Ltd. (NYSE: RE), Loews Corp.(NYSE: L), Omega Healthcare Investors Inc. (NYSE: OHI), RCI Hospitality Holdings Inc.(NYSE: RICK), Restaurant Brands International Inc. (NYSE: QSR), and Vornado Realty Trust (NYSE: VNO).

    Follow Money MorningonFacebook, Twitter, and LinkedIn.

Top 10 Medical Stocks To Own For 2021: Codorus Valley Bancorp, Inc(CVLY)

Codorus Valley Bancorp, Inc. (“Codorus Valley” or the “Corporation”) is a Pennsylvania business corporation, incorporated on October 7, 1986. On March 2, 1987, Codorus Valley became a bank holding company under the Bank Holding Company Act of 1956, as amended. PeoplesBank, A Codorus Valley Company (“PeoplesBank”) is its wholly owned bank subsidiary. The Corporation’s business consists primarily of managing PeoplesBank, and its principal source of income is dividends received from PeoplesBank. The Corporation also wholly-owns two non-bank subsidiaries, SYC Realty Co., Inc., a subsidiary for holding certain foreclosed assets pending liquidation, and CVLY Corp., which may be used, as needed, for the financial and legal management of acquisition transactions. On December 31, 2015, Codorus Valley had total consolidated assets of $1.46 billion, total deposits and other liabilities of $1.3 billion, and total shareholders’ equity of $159,141,000.   Advisors’ Opinion:

  • [By Logan Wallace]

    Codorus Valley Bancorp (NASDAQ:CVLY) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Friday.

  • [By Logan Wallace]

    Codorus Valley Bancorp, Inc. (NASDAQ:CVLY) declared a quarterly dividend on Tuesday, July 10th, NASDAQ reports. Investors of record on Tuesday, July 24th will be given a dividend of 0.155 per share by the financial services provider on Tuesday, August 14th. This represents a $0.62 dividend on an annualized basis and a dividend yield of 2.05%. The ex-dividend date of this dividend is Monday, July 23rd.

Top 10 Medical Stocks To Own For 2021: First Connecticut Bancorp, Inc.(FBNK)

First Connecticut Bancorp, Inc. operates as the holding company for Farmington Bank that provides various commercial and consumer banking services to businesses, individuals, and governments in the United States. The company offers various deposit instruments, including checking, savings, money market savings, and negotiable order of withdrawal accounts, as well as fixed-rate time deposits. It also provides one-to-four family residential real estate loans; commercial real estate loans; construction loans, such as commercial construction loans and real estate subdivision development loans to developers, licensed contractors, and builders for the construction and development of commercial real estate projects and residential properties, as well as loans to individuals and contractors for the construction and acquisition of personal residences; and commercial loans comprising term loans, revolving lines of credit for working capital needs, equipment lines of credit to facilitate the purchase of equipment, and letters of credit. In addition, the company offers home equity loans and home equity lines of credit secured by owner-occupied one-to-four family residences; and consumer loans, including installment, demand, revolving credit, and collateral loans, as well as resort loans. Further, it provides wealth management services. As of May 20, 2015, the company operated 22 branch locations in central Connecticut. It also operates four limited services offices, two stand-alone ATM facilities, and one commercial loan office. First Connecticut Bancorp, Inc. was founded in 1851 and is based in Farmington, Connecticut.

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on First Connecticut Bancorp (FBNK)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Spark Investment Management LLC decreased its position in First Connecticut Bancorp Inc (NASDAQ:FBNK) by 20.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,400 shares of the bank’s stock after selling 2,700 shares during the period. Spark Investment Management LLC owned 0.07% of First Connecticut Bancorp worth $318,000 at the end of the most recent quarter.

  • [By Shane Hupp]

    Wells Fargo & Company MN boosted its holdings in shares of First Connecticut Bancorp Inc (NASDAQ:FBNK) by 8.6% in the first quarter, Holdings Channel reports. The institutional investor owned 148,333 shares of the bank’s stock after purchasing an additional 11,719 shares during the quarter. Wells Fargo & Company MN’s holdings in First Connecticut Bancorp were worth $3,798,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Jordan Wathen]

    Shares of First Connecticut Bancorp Inc. (NASDAQ:FBNK) are soaring today, rising by more than 19% as of 11:00 a.m. EDT on news of an acquisition. The parent company ofFarmington Bank will be acquired by People’s United Financial (NASDAQ:PBCT) in an all-stock transaction valued at $544 million.

Top 10 Medical Stocks To Own For 2021: Nymox Pharmaceutical Corporation(NYMX)

Nymox Pharmaceutical Corporation, incorporated on May 30, 1995, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the aging population segment. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also has a range of patent portfolio covering its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer’s disease. The Company’s subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert.

The Company’s NicAlert and TobacAlert are the test strips, which determine whether a person is using tobacco products (NicAlert) or has been exposed to second-hand smoke (TobacAlert). Both NicAlert and TobacAlert provide a read-out of levels of cotinine, a by-product of the body’s breakdown of nicotine and regarded as the indicator of tobacco exposure for smokers and non-smokers. The technology can be used with saliva, as well as urine samples in order to detect tobacco product use. The Company’s AlzheimAlert is a urine assay that can aid physicians in the diagnosis of Alzheimer’s disease. The Company has developed a kit version of the AlzheimAlert assay for sale in Europe. The kit allows clinical reference laboratories to perform the AlzheimAlert assay on site with urine samples sent directly to the laboratory.

The Company is developing treatments for BPH. The Company’s lead candidate NX-1207 completed a multi-center, double-blind, placebo-controlled Phase II trial. The ! Company is in the process of further data analysis and assessments of the two studies. The Company is also developing NX-1207 as a focal treatment for certain types of cancer. The Company initiated a Phase II clinical trial in the United States. The Company enrolled approximately 147 patients at over 28 clinical centers across the United States to evaluate its NX-1207 drug for the treatment of low-grade localized prostate cancer.

The Company competes with LabCorp, Quest Diagnostics, OraSure Technologies Inc., Abraxis LLC, Roche Diagnostics, Abbott, Siemens Medical Solutions, Mossman & Associates Ltd, GFC Diagnostics Ltd., Lilly and GE Healthcare.

Advisors’ Opinion:

  • [By Logan Wallace]

    IDEXX Laboratories (NASDAQ: IDXX) and Nymox Pharmaceutical (NASDAQ:NYMX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Top 10 Medical Stocks To Own For 2021: Mitcham Industries Inc.(MIND)

Mitcham Industries, Inc., through its subsidiaries, engages in the leasing, sale, and service of geophysical and other equipment to the seismic industry worldwide. The company operates in two segments, Equipment Leasing and Seamap. The Equipment Leasing segment leases seismic equipment for short-term leasing primarily to seismic data acquisition contractors and oil field service providers. Its land equipment lease pool includes seismic recording land channels, geophones and cables, and other peripheral equipment; marine seismic equipment lease pool comprises streamers, air compressors, air guns, streamer positioning equipment, energy source controllers, and other equipment; and downhole equipment lease pool consist of downhole seismic tools. This segment is also involved in the sale of new seismic equipment of other manufacturers; heli-pickers and related equipment used in the deployment and retrieval of seismic equipment by helicopter; and equipment, consumables, systems integration, engineering hardware, and software maintenance support services to the seismic, hydrographic, oceanographic, environmental, and defense industries, as well as sells used equipment from its lease pool. The Seamap segment designs, manufactures, and sells a range of products for the marine seismic industry. Its products include GunLink seismic source acquisition and control systems, which are designed to provide operators of marine seismic surveys with precise control of energy sources; and BuoyLink RGPS tracking systems that are used to offer precise positioning of seismic sources and streamers. The company was founded in 1987 and is headquartered in Huntsville, Texas.

Advisors’ Opinion:

  • [By Stephan Byrd]

    First Wilshire Securities Management Inc. lowered its position in shares of Mitcham Industries, Inc. (NASDAQ:MIND) by 5.0% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 324,169 shares of the company’s stock after selling 17,005 shares during the quarter. First Wilshire Securities Management Inc. owned about 2.68% of Mitcham Industries worth $1,303,000 at the end of the most recent reporting period.

  • [By Logan Wallace]

    Teton Advisors Inc. lifted its stake in Mitcham Industries, Inc. (NASDAQ:MIND) by 22.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 140,069 shares of the company’s stock after purchasing an additional 26,000 shares during the quarter. Teton Advisors Inc. owned about 1.16% of Mitcham Industries worth $563,000 at the end of the most recent reporting period.

Top 10 Medical Stocks To Own For 2021: Applied Materials, Inc.(AMAT)

Applied Materials, Inc. (Applied), incorporated on March 18, 1987, provides manufacturing equipment, services and software to the semiconductor, display, solar photovoltaic (PV) and related industries across the world. The Company operates in four segments: Silicon Systems, Applied Global Services, Display, and Energy and Environmental Solutions. Its manufacturing activities consist of assembly, test and integration of various commercial parts, components and subassemblies that are used to manufacture systems. The Company caters to customers, including manufacturers of semiconductor chips, liquid crystal and other displays, solar PV cells, and other electronic devices. It has implemented a distributed manufacturing model under which manufacturing and supply chain activities are conducted in various countries, including Germany, Israel, Italy, Singapore, Taiwan, the United States and other countries in Asia.

Silicon Systems

The Company’s Silicon Systems segment develops, manufactures and sells a range of manufacturing equipment used to fabricate semiconductor chips, also referred to as integrated circuits (ICs). The Silicon Systems segment includes semiconductor capital equipment for deposition, etch, ion implantation, rapid thermal processing, chemical mechanical planarization, metrology and inspection, and wafer packaging. The majority of its new equipment sales are to integrated device manufacturers and foundries across the world. Its transistor and interconnect products and technologies have enabled various generations of device scaling from planar transistors to three-dimensional (3D) multi-gate FinFET transistors. It offers products and technologies for transistor and interconnect fabrication, including epitaxy, ion implantation, oxidation and nitridation, rapid thermal processing, chemical vapor deposition, physical vapor deposition, chemical mechanical planarization and electrochemical deposition. Many of these process steps are used multiple times throughout the semic! onductor chip fabrication process. Its Transistor and Interconnect Technologies’ products include Centura RP Epi, VIISta Systems, Vantage Systems and Raider Platform. It offers patterning and packaging products and systems that enable the transfer of patterns onto device structures, making it possible to etch masks used for photolithography, and perform deposition, etching and related processes. Its Patterning and Packaging Technologies’ include Olympia System, Producer Systems, and Centris and Producer Systems. It offers a suite of metrology, inspection and review systems for front- and back-end-of-line applications. These systems’ imaging capabilities and algorithms employ optical and e-beam technologies to meet the technical demands, such as self-aligned double and quad patterning, extreme ultraviolet layers, measurement-intensive optimal proximity correction mask qualification, and 3D architectures. The Company delivers capabilities that enable chipmakers to establish statistical process control, ramp up production runs rapidly and achieve high production yields. Its Imaging and Process Control Technologies’ products include SEMVision G6 Defect Analysis and Aera4 Mask Inspection.

Applied Global Services

The Company’s Applied Global Services (AGS) segment provides integrated solutions to optimize equipment and fab performance and productivity, including spares, upgrades, services, remanufactured earlier generation equipment and factory automation software for semiconductor, display and solar products. Customer demand for products and services is fulfilled through a global distribution system with trained service engineers located in close proximity to customer sites in various countries to support approximately 33,000 installed Applied semiconductor, display and solar manufacturing systems across the world. It offers various services and products under the Applied Global Services segment, including certified services, fab consulting, parts programs, subfab equipment, legacy ! equipment! and automation software.

Display

The Company’s Display segment consists of products for manufacturing liquid crystal displays (LCDs), organic light-emitting diodes (OLEDs), and other display technologies for televisions, personal computers (PCs), tablets, smart phones and other consumer-oriented devices. The Display segment offers various technologies and products, including array test, chemical vapor deposition (CVD) and physical vapor deposition (PVD). Its products include Electron Beam Array Tester, AKT PECVD Systems, AKT Aristo and PiVot Systems.

Energy and Environmental Solutions

The Company’s Energy and Environmental Solutions segment includes products for fabricating crystalline-silicon (c-Si) solar PV cells, as well as high throughput roll-to-roll deposition equipment for flexible electronics, packaging and other applications. The technologies and products offered in the Energy and Environmental Solutions segment include Cell Manufacturing and Roll-to-Roll WEB Coating. It offers fine Line Double Print process, which enables solar manufacturers to produce cells with less paste. Its Roll-to-Roll coating systems provide production solutions for packaging, flexible electronics and security industries. WEB systems utilize physical vapor deposition, thermal evaporation, chemical vapor deposition and e-beam technology to deposit tiny layers of metal onto flexible substrates. Its products include Baccini Systems, TopBeam, TopMet and SmartWeb Systems.

Advisors’ Opinion:

  • [By Ashraf Eassa]

    BothUniversal Display(NASDAQ:OLED) andApplied Materials(NASDAQ:AMAT) generate revenue by providing display manufacturers with products required to build display panels.

  • [By John Bromels, Rich Smith, and Tyler Crowe]

    We asked three of our Motley Fool contributors what solar stocks they’d keep an eye on this month, and they came back withEnphase Energy(NASDAQ:ENPH),Applied Materials(NASDAQ:AMAT), andSolarEdge Technologies(NASDAQ:SEDG). Here’s why they think you should keep these solar companies on your radar.

  • [By Chris Lange]

    Short interest in Applied Materials Inc. (NASDAQ: AMAT) decreased to 13.14 million shares. The previous reading was 13.87 million. Shares were trading at $38.78, in a 52-week range of $28.79 to $62.40.

  • [By Motley Fool Transcription]

    Applied Materials, Inc. (NASDAQ:AMAT) Q1 2019 Earnings Conference Call Feb. 14, 2018, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top 10 Medical Stocks To Own For 2021: Blueprint Medicines Corporation(BPMC)

Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The companys lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4. It is also developing a drug candidate to target RET, a receptor tyrosine kinase that can becomes abnormally activated when a portion of the gene that encodes RET is joined to part of another gene; and RET resistant mutants that would arise from treatment with first generation therapies, as well as a program that targets rare genetic diseases. The company has a research, development, and commercialization agreement with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is based in Cambridge, Massachusetts.

Advisors’ Opinion:

  • [By Max Byerly]

    Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Tuesday, February 26th. The biotechnology company reported ($1.83) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.76) by ($0.07). The firm had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $1.77 million. Blueprint Medicines had a negative net margin of 455.15% and a negative return on equity of 36.72%. The company’s quarterly revenue was down 36.7% on a year-over-year basis. During the same period in the previous year, the company earned ($1.23) EPS. As a group, equities research analysts forecast that Blueprint Medicines Corp will post -5.35 EPS for the current fiscal year.

    WARNING: “Eagle Asset Management Inc. Cuts Stake in Blueprint Medicines Corp (BPMC)” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at www.tickerreport.com/banking-finance/4188921/eagle-asset-management-inc-cuts-stake-in-blueprint-medicines-corp-bpmc.html.

    About Blueprint Medicines

  • [By Motley Fool Transcribers]

    Blueprint Medicines Corp (NASDAQ:BPMC)Q42018 Earnings Conference CallFeb. 26, 2019, 8:30 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top 10 Medical Stocks To Own For 2021: ZIOPHARM Oncology Inc(ZIOP)

ZIOPHARM Oncology, Inc., incorporated on May 16, 2005, is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. The Company’s clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. Its Ad-RTS-IL-12 + veledimex uses gene delivery system to produce interleukin-12 (IL-12), a potent, naturally occurring anti-cancer protein. The Company’s initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.

The Company in collaboration with Intrexon Corporation is focused on chimeric antigen receptor T cell (CAR+ T) products. The Company in collaboration with Intrexon plans to develop treatments for graft-versus-host disease (GvHD), a major complication of allogeneic hematopoietic stem-cell transplantation (HSCT), which impairs the quality of life and survival of many recipients. Allogeneic HSCT is used for the treatment of various diseases, including hematological malignancies, immunological deficiencies, as well as non-malignant conditions. Approximately 40 to 60% of HSCT recipients develop GvHD, either acute or chronic, when immune (graft) cells in a transplant patient recognize their engrafted host as foreign and attack the patient’s (host) cells. Immunosuppressive agents and systemic steroids routinely used to treat GvHD have limited efficacy and toxicity. Human studies have shown that administration of low-dose subcutaneous IL-2 in patients with steroid-refractory GvHD acts through Tregs to ameliorate its manifestations.

Ad-RTS-IL-12 + veledimex

The Company’s Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. The Company is evaluating Ad-RTS-IL-12 + veledimex, in brain cancer and breast cancer. It h! as developed an adenoviral vector, Ad-RTS-IL-12, administered intratumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Gene expression and subsequent IL-12 protein production is tightly controlled by the activator ligand veledimex.

Ad-RTS-IL-12 + veledimex for malignant glioma

The Company has initiated the Phase I study for malignant glioma. The Food and Drug Administration (FDA) granted orphan drug designation of Ad-RTS-IL-12 + veledimex for the treatment of malignant glioma.

Ad-RTS-IL-12 + veledimex for metastatic breast cancer and melanoma

The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. The Company has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer.

The Company competes with Novartis/University of Pennsylvania, Bluebird bio/Celgene/Baylor College of Medicine, Kite Pharma/National Cancer Institute, Juno Therapeutics/Fred Hutchinson Cancer Research Center/Memorial Sloan-Kettering Cancer Center/Seattle Children’s Research Institute, Cellectis/Pfizer, Adaptimmune/GSK, Celgene, NantKwest, Amgen, AstraZeneca, Bristol-Myers, Incyte, Merck and Roche.

Advisors’ Opinion:

  • [By Logan Wallace]

    A number of hedge funds have recently bought and sold shares of ZIOP. MSD Partners L.P. increased its position in ZIOPHARM Oncology by 222.1% during the 4th quarter. MSD Partners L.P. now owns 10,986,258 shares of the biotechnology company’s stock valued at $20,544,000 after buying an additional 7,575,758 shares in the last quarter. FMR LLC bought a new position in ZIOPHARM Oncology during the 3rd quarter valued at approximately $1,647,000. Ibex Investors LLC bought a new position in ZIOPHARM Oncology during the 4th quarter valued at approximately $755,000. Bank of America Corp DE increased its position in ZIOPHARM Oncology by 198.1% during the 2nd quarter. Bank of America Corp DE now owns 99,565 shares of the biotechnology company’s stock valued at $301,000 after buying an additional 201,063 shares in the last quarter. Finally, Old West Investment Management LLC increased its position in ZIOPHARM Oncology by 784.7% during the 4th quarter. Old West Investment Management LLC now owns 223,319 shares of the biotechnology company’s stock valued at $417,000 after buying an additional 198,077 shares in the last quarter. 40.12% of the stock is owned by institutional investors.

    WARNING: “ZIOPHARM Oncology (ZIOP) Stock Price Up 8.9%” was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at www.tickerreport.com/banking-finance/4199573/ziopharm-oncology-ziop-stock-price-up-8-9.html.

    ZIOPHARM Oncology Company Profile (NASDAQ:ZIOP)

  • [By Motley Fool Transcribers]

    Ziopharm Oncology Inc (NASDAQ:ZIOP)Q42018 Earnings Conference CallMarch 05, 2019, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Keith Speights]

    Strongbridge Biopharma (NASDAQ:SBBP), Endo International plc (NASDAQ:ENDP), andZiopharm Oncology (NASDAQ:ZIOP)saw theirshare prices soar by 27% or more over the last several days after the companies provided second-quarter updates. Here’s what was in those updates that caused the stocks to move — and whether or not any of these biotechs are buys now.

Top 10 Medical Stocks To Own For 2021: Snap-On Incorporated(SNA)

Snap-on Incorporated manufactures and markets tools, equipment, diagnostics, and repair information and systems solutions for professional users worldwide. The company operates through Commercial & Industrial Group, Snap-on Tools Group, Repair Systems & Information Group, and Financial Services segments. It offers hand tools, such as wrenches, sockets, ratchet wrenches, pliers, screwdrivers, punches and chisels, saws and cutting tools, pruning tools, torque measuring instruments, and other products; power tools, such as cordless, pneumatic, hydraulic, and corded tools comprising impact wrenches, ratchets, screwdrivers, drills, sanders, grinders, and related products; and tool storage products comprising tool chests, roll cabinets, and other products. The company also provides handheld and PC-based diagnostic products, service and repair information products, diagnostic software solutions, electronic parts catalogs, business management systems and services, point-of-sale systems, integrated systems for vehicle service shops, original equipment manufacturer purchasing facilitation services, and warranty management systems and analytics. In addition, it offers solutions for diagnosis and service of vehicles and industrial equipment for various products, such as wheel alignment equipment, wheel balancers, tire changers, vehicle lifts, test lane systems, collision repair equipment, air conditioning service equipment, brake service equipment, fluid exchange equipment, transmission troubleshooting equipment, safety testing equipment, battery chargers, and hoists. Further, the company provides financing programs to facilitate the sales of its products. It serves aviation and aerospace, agriculture, construction, government and military, mining, natural resources, power generation, and technical education industries, as well as vehicle dealerships and repair centers. The company was founded in 1920 and is headquartered in Kenosha, Wisconsin.

Advisors’ Opinion:

  • [By Max Byerly]

    Whittier Trust Co. of Nevada Inc. raised its stake in shares of Snap-on Incorporated (NYSE:SNA) by 4.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 1,859 shares of the company’s stock after purchasing an additional 73 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in Snap-on were worth $270,000 as of its most recent filing with the SEC.

  • [By Lee Samaha]

    Shares in tool and equipment manufacturer Snap-on (NYSE:SNA) rose 14.2% in January, according to data provided by S&P Global Market Intelligence. However, it would be remiss not to point out that the stock slumped after a disappointing set of fourth-quarter earnings released in the first week of February.

  • [By Motley Fool Transcribers]

    Snap-On Inc (NYSE:SNA)Q42018 Earnings Conference CallFeb. 07, 2019, 10:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator